Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Bladder Cancer, April 2018

Free Subscription


Abstracts

Retrieve all available abstracts of the following 87 articles:
HTML format


 

Single Articles

  1. LI Q, Li C, Chen J, Liu P, et al
    High expression of long noncoding RNA NORAD indicates a poor prognosis and promotes clinical progression and metastasis in bladder cancer.
    Urol Oncol. 2018 Mar 28. pii: S1078-1439(18)30076.
    Abstract    

    Abstract available

  2. KASSOUF W, Aprikian A, Saad F, Breau RH, et al
    Improving patient journey and quality of care: Summary from the 2nd Bladder Cancer Canada-Canadian Urological Association-Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting.
    Can Urol Assoc J. 2018 Mar 19. pii: cuaj.5246. doi: 10.5489/cuaj.5246.
    Abstract    



  3. GISLEFOSS RE, Stenehjem JS, Hektoen HH, Andreassen BK, et al
    Vitamin D, obesity and leptin in relation to bladder cancer incidence and survival: prospective protocol study.
    BMJ Open. 2018;8:e019309.
    Abstract    

    Abstract available

  4. MOSCHINI M, Arbelaez E, Cornelius J, Mattei A, et al
    Pattern of node metastases in patients treated with radical cystectomy and extended or superextended pelvic lymph node dissection due to bladder cancer.
    Urol Oncol. 2018 Mar 27. pii: S1078-1439(18)30078.
    Abstract    

    Abstract available

  5. ZHAO J, Shi L, Zeng S, Ma C, et al
    Importin-11 overexpression promotes the migration, invasion, and progression of bladder cancer associated with the deregulation of CDKN1A and THBS1.
    Urol Oncol. 2018 Mar 27. pii: S1078-1439(18)30077.
    Abstract    

    Abstract available

  6. ECKSTEIN M, Wirtz RM, Pfannstil C, Wach S, et al
    A multicenter round robin test of PD-L1 expression assessment in urothelial bladder cancer by immunohistochemistry and RT-qPCR with emphasis on prognosis prediction after radical cystectomy.
    Oncotarget. 2018;9:15001-15014.
    Abstract    

    Abstract available

  7. LIAN J, Lin SH, Ye Y, Chang DW, et al
    Serum microRNAs as predictors of risk for non-muscle invasive bladder cancer.
    Oncotarget. 2018;9:14895-14908.
    Abstract    

    Abstract available

  8. MOTA P, Sousa PM, Botelho F, Carvalho-Dias E, et al
    [Smoking Cessation after Bladder Cancer Diagnosis].
    Acta Med Port. 2018;31:101-108.
    Abstract    

    Abstract available

  9. WANG C, Xu Z, Li W, Jiao Y, et al
    [Analysis of the correlation between E2F3 expression and the number of tumor-infiltrating CD8(+)T cells in invasive bladder cancer tissues].
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2018;34:1-8.
    Abstract    

    Abstract available

  10. KIM WT, Seo SP, Byun YJ, Kang HW, et al
    The Anticancer Effects of Garlic Extracts on Bladder Cancer Compared to Cisplatin: A Common Mechanism of Action via Centromere Protein M.
    Am J Chin Med. 2018 Mar 29:1-17. doi: 10.1142/S0192415X18500362.
    Abstract    

    Abstract available

  11. LI Z, Niu Y
    Association between lncRNA H19 (rs217727, rs2735971 and rs3024270) polymorphisms and the risk of bladder cancer in Chinese population.
    Minerva Urol Nefrol. 2018 Mar 28. pii: S0393-2249.18.03004.
    Abstract    

    Abstract available

  12. WINERDAL ME, Krantz D, Hartana CA, Zirakzadeh AA, et al
    Urinary Bladder Cancer Tregs Suppress MMP2 and Potentially Regulate Invasiveness.
    Cancer Immunol Res. 2018 Mar 27. pii: 2326-6066.CIR-17-0466.
    Abstract    

    Abstract available

  13. HASHMI AA, Hussain ZF, Irfan M, Edhi MM, et al
    Cytokeratin 5/6 expression in bladder cancer: association with clinicopathologic parameters and prognosis.
    BMC Res Notes. 2018;11:207.
    Abstract    

    Abstract available

  14. KIM WT, Kim YH, Jeong P, Seo SP, et al
    Urinary cell-free nucleic acid IQGAP3: a new non-invasive diagnostic marker for bladder cancer.
    Oncotarget. 2018;9:14354-14365.
    Abstract    

    Abstract available

  15. HUANG L, Luan T, Chen Y, Bao X, et al
    LASS2 regulates invasion and chemoresistance via ERK/Drp1 modulated mitochondrial dynamics in bladder cancer cells.
    J Cancer. 2018;9:1017-1024.
    Abstract    

    Abstract available

  16. LIU TJ, Zhang JC, Gao XZ, Tan ZB, et al
    Clinical research of goal-directed fluid therapy in elderly patients with radical resection of bladder cancer.
    J Cancer Res Ther. 2018;14.
    Abstract    

    Abstract available

  17. WU GJ, Bao JS, Yue ZJ, Zeng FC, et al
    Elevated expression of matrix metalloproteinase-9 is associated with bladder cancer pathogenesis.
    J Cancer Res Ther. 2018;14.
    Abstract    

    Abstract available

  18. CHEN Y, Wang H, Zuo Y, Li N, et al
    A novel monoclonal antibody KMP1 has potential antitumor activity of bladder cancer by blocking CD44 in vivo and in vitro.
    Cancer Med. 2018 Mar 25. doi: 10.1002/cam4.1446.
    Abstract    

    Abstract available

  19. LENIS AT, Asanad K, Blaibel M, Donin NM, et al
    Association between Metabolic Syndrome and Recurrence of Nonmuscle Invasive Bladder Cancer following bacillus Calmette-Guerin Treatment.
    Urol Pract. 2018;5:132-138.
    Abstract    

    Abstract available

  20. KOSHKIN VS, Barata PC, Rybicki LA, Zahoor H, et al
    Feasibility of Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer Patients With Diminished Renal Function.
    Clin Genitourin Cancer. 2018 Feb 22. pii: S1558-7673(18)30118.
    Abstract    

    Abstract available

  21. AUDENET F, Attalla K, Sfakianos JP
    The evolution of bladder cancer genomics: What have we learned and how can we use it?
    Urol Oncol. 2018 Mar 21. pii: S1078-1439(18)30074.
    Abstract    

    Abstract available

  22. KANG HW, Seo SP, Byun YJ, Piao XM, et al
    Molecular Progression Risk Score for Prediction of Muscle Invasion in Primary T1 High-Grade Bladder Cancer.
    Clin Genitourin Cancer. 2018 Feb 23. pii: S1558-7673(18)30117.
    Abstract    

    Abstract available

  23. ROSATO V, Negri E, Serraino D, Montella M, et al
    Processed Meat and Risk of Renal Cell and Bladder Cancers.
    Nutr Cancer. 2018 Mar 23:1-7. doi: 10.1080/01635581.2018.1445764.
    Abstract    

    Abstract available

  24. LEE MY, Yeon A, Shahid M, Cho E, et al
    Reprogrammed lipid metabolism in bladder cancer with cisplatin resistance.
    Oncotarget. 2018;9:13231-13243.
    Abstract    

    Abstract available

  25. LIAO CC, Chen SC, Huang HP, Wang CJ, et al
    Gallic acid inhibits bladder cancer cell proliferation and migration via regulating fatty acid synthase (FAS).
    J Food Drug Anal. 2018;26:620-627.
    Abstract    

    Abstract available

  26. TOMISAKI I, Kubo T, Minato A, Fujimoto N, et al
    Efficacy and Tolerability of Bacillus Calmette-Guerin Therapy as the First-Line Therapy for Upper Urinary Tract Carcinoma In Situ.
    Cancer Invest. 2018;36:152-157.
    Abstract    

    Abstract available

  27. MIYAMOTO K, Ito A, Wakabayashi M, Eba J, et al
    A Phase III trial of a single early intravesical instillation of pirarubicin to prevent bladder recurrence after radical nephroureterectomy for upper tract urothelial carcinoma (JCOG1403, UTUC THP Phase III).
    Jpn J Clin Oncol. 2018;48:94-97.
    Abstract    

    Abstract available

  28. TUO Z, Zhang J, Xue W
    LncRNA TP73-AS1 predicts the prognosis of bladder cancer patients and functions as a suppressor for bladder cancer by EMT pathway.
    Biochem Biophys Res Commun. 2018 Apr 3. pii: S0006-291X(18)30773.
    Abstract    

    Abstract available

  29. LEE SH, Hu W, Matulay JT, Silva MV, et al
    Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer.
    Cell. 2018;173:515-528.
    Abstract    

    Abstract available

  30. THOMA C
    Bladder cancer: Neuroendocrine disease genomics.
    Nat Rev Urol. 2018 Apr 5. pii: nrurol.2018.42. doi: 10.1038/nrurol.2018.
    Abstract    



  31. SWEIS RF, Zha Y, Pass L, Heiss B, et al
    Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer.
    J Immunother Cancer. 2018;6:24.
    Abstract    

    Abstract available

  32. GAO JM, Huang LZ, Huang ZG, He RQ, et al
    Clinical value and potential pathways of miR-183-5p in bladder cancer: A study based on miRNA-seq data and bioinformatics analysis.
    Oncol Lett. 2018;15:5056-5070.
    Abstract    

    Abstract available

  33. CRABB S, Danson SJ, Catto JWF, McDowell C, et al
    SPIRE - combining SGI-110 with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer: study protocol for a phase Ib/randomised IIa open label clinical trial.
    Trials. 2018;19:216.
    Abstract    

    Abstract available

  34. INAMURA K
    Bladder Cancer: New Insights into Its Molecular Pathology.
    Cancers (Basel). 2018;10.
    Abstract    

    Abstract available

  35. ZHU Z, Xu L, Wan Y, Zhou J, et al
    Inhibition of E-cadherin expression by lnc-RNA H19 to facilitate bladder cancer metastasis.
    Cancer Biomark. 2018 Mar 19. pii: CBM170998. doi: 10.3233/CBM-170998.
    Abstract    

    Abstract available

  36. LIANG Z, Xin R, Yu Y, Wang R, et al
    Diagnostic value of urinary survivin as a biomarker for bladder cancer: a systematic review and meta-analysis of published studies.
    World J Urol. 2018 Apr 2. pii: 10.1007/s00345-018-2285.
    Abstract    

    Abstract available

  37. MAMMEN S, Krishna S, Quon M, Shabana WM, et al
    Diagnostic Accuracy of Qualitative and Quantitative Computed Tomography Analysis for Diagnosis of Pathological Grade and Stage in Upper Tract Urothelial Cell Carcinoma.
    J Comput Assist Tomogr. 2018;42:204-210.
    Abstract    

    Abstract available

  38. WANG JS, Liu QH, Cheng XH, Zhang WY, et al
    The long noncoding RNA ZFAS1 facilitates bladder cancer tumorigenesis by sponging miR-329.
    Biomed Pharmacother. 2018;103:174-181.
    Abstract    

    Abstract available

  39. STRUCK JP, Karl A, Schwentner C, Herrmann TRW, et al
    [En bloc resection and vaporization techniques for the treatment of bladder cancer].
    Urologe A. 2018 Apr 12. pii: 10.1007/s00120-018-0625.
    Abstract    

    Abstract available

  40. TSELIS N, Prott FJ, Ott O, Weiss C, et al
    [Radiochemotherapy for invasive bladder cancer : An update].
    Urologe A. 2018 Apr 12. pii: 10.1007/s00120-018-0628.
    Abstract    

    Abstract available

  41. TEO MY, Rosenberg JE
    Perioperative Immunotherapy in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma.
    Urol Clin North Am. 2018;45:287-295.
    Abstract    

    Abstract available

  42. ACHKAR T, Parikh RA
    Adjuvant Therapy in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma.
    Urol Clin North Am. 2018;45:257-266.
    Abstract    

    Abstract available

  43. ZAINFELD D, Shah A, Daneshmand S
    Enhanced Recovery After Surgery Pathways: Role and Outcomes in the Management of Muscle Invasive Bladder Cancer.
    Urol Clin North Am. 2018;45:229-239.
    Abstract    

    Abstract available

  44. SATHIANATHEN NJ, Risk MC, Konety BR
    Lymphadenectomy for Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Cell Carcinoma.
    Urol Clin North Am. 2018;45:215-228.
    Abstract    

    Abstract available

  45. TABAYOYONG W, Li R, Gao J, Kamat A, et al
    Optimal Timing of Chemotherapy and Surgery in Patients with Muscle-Invasive Bladder Cancer and Upper Urinary Tract Urothelial Carcinoma.
    Urol Clin North Am. 2018;45:155-167.
    Abstract    

    Abstract available

  46. MOSSANEN M, Chang SL, Kimm S, Sonpavde GP, et al
    Current Staging Strategies for Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Cell Carcinoma.
    Urol Clin North Am. 2018;45:143-154.
    Abstract    

    Abstract available

  47. CRETA M, Longo N, Imbimbo C, Imperatore V, et al
    Health-related quality of life in bladder cancer patients undergoing radical cystectomy and urinary stoma: still many gaps.
    Transl Androl Urol. 2018;7.
    Abstract    



  48. KIM AH, Kim SP
    Surviving travel or travelling to survive: the association of travel distance with survival in muscle invasive bladder cancer.
    Transl Androl Urol. 2018;7.
    Abstract    



  49. SORIA F, Gontero P
    How to assess and improve health-related quality of life in bladder cancer patients.
    Transl Androl Urol. 2018;7.
    Abstract    



  50. LIPPI G, Del Rio D
    Nutritional habits and bladder cancer.
    Transl Androl Urol. 2018;7.
    Abstract    



  51. HAQUE W, Butler EB, Teh BS
    Clinical benefit to regionalization of care for muscle invasive bladder cancer.
    Transl Androl Urol. 2018;7.
    Abstract    



  52. FONTEYNE V, Rammant E, Decaestecker K
    Selecting candidates for early discharge after radical cystectomy for bladder cancer.
    Transl Androl Urol. 2018;7.
    Abstract    



  53. HAMEED DA, Yassa HA, Agban MN, Hanna RT, et al
    Genetic aberrations of the K-ras proto-oncogene and in bladder cancer in relation to pesticide exposure.
    Environ Sci Pollut Res Int. 2018 Apr 12. pii: 10.1007/s11356-018-1840.
    Abstract    

    Abstract available

  54. SYLVESTER R
    A single immediate instillation of chemotherapy for non-muscle invasive bladder cancer: in all patients?
    Transl Androl Urol. 2018;7.
    Abstract    



  55. OOSTERLINCK W, Decaestecker K
    Editorial on the value of an immediate intravesical instillation of mitomycin C in patients with non-muscle-invasive bladder cancer.
    Transl Androl Urol. 2018;7.
    Abstract    



  56. BANERJEE S, Banerjee S
    Robot-assisted laparoscopic implantation of brachytherapy catheters in bladder cancer recent interests and prospective.
    Transl Androl Urol. 2018;7.
    Abstract    



  57. TAN WS, Tan WP
    Urinary biomarker for the detection of recurrence following non-muscle invasive bladder cancer: are we there yet?
    Transl Androl Urol. 2018;7.
    Abstract    



  58. TAN Z, D'Costa NM, Raven PA, Chavez-Munoz C, et al
    Identification of hypoxic gene-signature as a prognostic and predictive biomarker to determine effective therapy in high risk bladder cancer patients.
    Transl Androl Urol. 2018;7.
    Abstract    



  59. MORALES-BARRERA R, Gonzalez M, Suarez C, Carles J, et al
    Detection of circulating tumor DNA for advanced bladder cancer: where are we going?
    Transl Androl Urol. 2018;7.
    Abstract    



  60. DOBBS RW, Abern MR
    A novel bladder cancer urinary biomarker: can it go where no marker has gone before?
    Transl Androl Urol. 2018;7.
    Abstract    



  61. IKUEROWO SO, Ojewuyi OO, Bioku MJ, Abolarinwa AA, et al
    Outcome of Mainz II Pouch Urinary Diversion after Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer: Our Experience.
    Niger J Surg. 2018;24:12-15.
    Abstract    

    Abstract available

  62. GORIKI A, Seiler R, Wyatt AW, Contreras-Sanz A, et al
    Unravelling disparate roles of NOTCH in bladder cancer.
    Nat Rev Urol. 2018 Apr 11. pii: 10.1038/s41585-018-0005.
    Abstract    

    Abstract available

  63. GOU L, Liu M, Xia J, Wan Q, et al
    BMP9 Promotes the Proliferation and Migration of Bladder Cancer Cells through Up-Regulating lncRNA UCA1.
    Int J Mol Sci. 2018;19.
    Abstract    

    Abstract available

  64. PU X, Zhu L, Fu Y, Fan Z, et al
    Companied P16 genetic and protein status together providing useful information on the clinical outcome of urinary bladder cancer.
    Medicine (Baltimore). 2018;97:e0353.
    Abstract    

    Abstract available

  65. HORN T, Krege S, Retz M
    [Advanced bladder cancer : From chemo- to immunotherapy].
    Urologe A. 2018 Apr 10. pii: 10.1007/s00120-018-0626.
    Abstract    

    Abstract available

  66. TSURUTA M, Ueda S, Yew PY, Fukuda I, et al
    Bladder cancer-associated cancer-testis antigen-derived long peptides encompassing both CTL and promiscuous HLA class II-restricted Th cell epitopes induced CD4(+) T cells expressing converged T-cell receptor genes in vitro.
    Oncoimmunology. 2018;7:e1415687.
    Abstract    

    Abstract available

  67. MARCH-VILLALBA JA, Panach-Navarrete J, Herrero-Cervera MJ, Alino-Pellicer S, et al
    hTERT mRNA expression in urine as a useful diagnostic tool in bladder cancer. Comparison with cytology and NMP22 BladderCheck Test(R).
    Actas Urol Esp. 2018 Apr 6. pii: S0210-4806(18)30050.
    Abstract    

    Abstract available

  68. KLAPHEKE A, Yap SA, Pan K, Cress RD, et al
    Sociodemographic disparities in chemotherapy treatment and impact on survival among patients with metastatic bladder cancer.
    Urol Oncol. 2018 Apr 5. pii: S1078-1439(18)30084.
    Abstract    

    Abstract available

  69. KIM S, Lee AJ, Yeo MK, Na YG, et al
    Clinicopathological Profiling of LC3B, an Autophagy Marker, and ESRRA (Estrogen-related Receptor-alpha) in Muscle-invasive Bladder Cancer.
    Anticancer Res. 2018;38:2429-2437.
    Abstract    

    Abstract available

  70. MATSUNAGA W, Ichikawa M, Nakamura A, Ishikawa T, et al
    Lentiviral Vector-mediated Gene Transfer in Human Bladder Cancer Cell Lines.
    Anticancer Res. 2018;38:2015-2020.
    Abstract    

    Abstract available

  71. MAKINO T, Izumi K, Natsagdorj A, Iwamoto H, et al
    Significance of Perioperative Chemotherapy in Squamous Cell Carcinoma of the Upper and Lower Urinary Tract.
    Anticancer Res. 2018;38:2241-2245.
    Abstract    

    Abstract available

  72. MOSSANEN M, Brown JC, Schrag D
    Well-being beyond the bladder. How do we improve the overall health of patients with bladder cancer?
    BJU Int. 2018;121:489-491.
    Abstract    



  73. LOTAN Y, Woldu SL, Sanli O, Black P, et al
    Modeling Cost-Effectiveness of a Biomarker-Based Approach to Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer.
    BJU Int. 2018 Mar 31. doi: 10.1111/bju.14220.
    Abstract    

    Abstract available

  74. FRANSEN VAN DE PUTTE EE, Bosschieter J, van der Kwast TH, Bertz S, et al
    The WHO 1973 classification system for grade is an Important prognosticator in T1 non-muscle-invasive bladder cancer.
    BJU Int. 2018 Apr 10. doi: 10.1111/bju.14238.
    Abstract    

    Abstract available

  75. CHA EK, Sfakianos JP, Sukhu R, Yee AM, et al
    Poor prognosis of bladder cancer patients with occult lymph node metastases treated with neoadjuvant chemotherapy.
    BJU Int. 2018 Apr 7. doi: 10.1111/bju.14242.
    Abstract    

    Abstract available

  76. ANDREASSEN BK, Grimsrud TK, Haug ES
    Bladder cancer survival: Women better off in the long run.
    Eur J Cancer. 2018;95:52-58.
    Abstract    

    Abstract available

  77. SARFATY M, Hall PS, Chan KKW, Virik K, et al
    Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer.
    Eur Urol. 2018 Mar 22. pii: S0302-2838(18)30182.
    Abstract    

    Abstract available

  78. MOSCHINI M, Sargos P
    Re: Adjuvant Sandwich Chemotherapy Plus Radiotherapy vs Adjuvant Chemotherapy Alone for Locally Advanced Bladder Cancer After Radical Cystectomy a Randomized Phase 2 Trial.
    Eur Urol. 2018 Apr 9. pii: S0302-2838(18)30203.
    Abstract    



  79. FABA OR, Breda A, Palou J
    Re: Value of an Immediate Intravesical Instillation of Mitomycin C in Patients with Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Randomised Study in 2243 patients.
    Eur Urol. 2018 Apr 7. pii: S0302-2838(18)30243.
    Abstract    



  80. LI C, Liu J, Zhang Q, Cui K, et al
    Upregulation of Ecadherin expression mediated by a novel dsRNA suppresses the growth and metastasis of bladder cancer cells by inhibiting beta-catenin/TCF target genes.
    Int J Oncol. 2018 Mar 29. doi: 10.3892/ijo.2018.4346.
    Abstract    

    Abstract available

  81. LIU M, Chen Y, Huang B, Mao S, et al
    Tumor-suppressing effects of microRNA-612 in bladder cancer cells by targeting malic enzyme 1 expression.
    Int J Oncol. 2018 Mar 29. doi: 10.3892/ijo.2018.4342.
    Abstract    

    Abstract available

  82. TATSUGAMI K
    Editorial Comment to Prediction models for progression of non-muscle-invasive bladder cancer: A review.
    Int J Urol. 2018;25:218-219.
    Abstract    



  83. BATURA D, Hashemzehi T, Colemeadow J
    A care bundle to improve perioperative mitomycin use in non-muscle-invasive bladder cancer.
    Int Urol Nephrol. 2018 Apr 2. pii: 10.1007/s11255-018-1863.
    Abstract    

    Abstract available

  84. CHANG SS
    Re: Phase III, Double-Blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First-Line Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer.
    J Urol. 2018;199:891-892.
    Abstract    



  85. CHANG SS
    Re: Comparative Effectiveness of Treatment Strategies for Bladder Cancer with Clinical Evidence of Regional Lymph Node Involvement.
    J Urol. 2018;199:891-892.
    Abstract    



  86. XIAO J, Niu S, Zhu J, Lv L, et al
    miR223p enhances multichemoresistance by targeting NET1 in bladder cancer cells.
    Oncol Rep. 2018 Apr 4. doi: 10.3892/or.2018.6355.
    Abstract    

    Abstract available

  87. BARBOSA ALA, Vermeulen SHHM, Aben KK, Grotenhuis AJ, et al
    Smoking intensity and bladder cancer aggressiveness at diagnosis.
    PLoS One. 2018;13:e0194039.
    Abstract    

    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design:


;